Marker Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 26, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 26, 2024

MRKR$0.99+10.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents


FORWARD LOOKING STATEMENTS · ii
Part I · ·
Item 1.	Business	1
Item 1A.	Risk Factors	28
Item 1B.	Unresolved Staff Comments	67
Item 1C.	Cybersecurity	68
Item 2.	Properties	69
Item 3.	Legal Proceedings	69
Item 4.	Mine Safety Disclosure	69
Part II
Item 5.	Market For Registrant’s Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities	70
Item 6.	[Reserved]	70
Item 7.	Management’s Discussion And Analysis Of Financial Condition And Results Of Operations	71
Item 7A.	Quantitative And Qualitative Disclosures About Market Risk	83
Item 8.	Financial Statements	83
Item 9.	Changes In And Disagreements With Accountants On Accounting And Financial Disclosure	83
Item 9A.	Controls And Procedures	84
Item 9B.	Other Information	85
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	85
Part III
Item 10.	Directors, Executive Officers And Corporate Governance	86
Item 11.	Executive Compensation	86
Item 12.	Security Ownership Of Certain Beneficial Owners And Management And Related Stockholder Matters	86
Item 13.	Certain Relationships And Related Transactions, And Director Independence	86
Item 14.	Principal Accounting Fees And Services	86
Part IV
Item 15.	Exhibits, Financial Statement Schedules	87
	Signatures	90

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Table of Contents